← All trials
NCT07075315
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2028
- Primary completion
- Dec 31, 2031
- Completion date
- Dec 31, 2031
- First posted
- Jul 20, 2025
- Last posted
- Aug 17, 2025
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Institute of Liver and Biliary Sciences, IndiaLead sponsor
- Indian Council of Medical ResearchCollaborator
- Institute of Liver and Biliary Sciences, IndiaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.